scispace - formally typeset
J

Julio Benítez

Researcher at University of Extremadura

Publications -  108
Citations -  4483

Julio Benítez is an academic researcher from University of Extremadura. The author has contributed to research in topics: Debrisoquine & Genotype. The author has an hindex of 40, co-authored 108 publications receiving 4357 citations. Previous affiliations of Julio Benítez include University of Illinois at Urbana–Champaign & Hospital Clínico San Carlos.

Papers
More filters
Journal ArticleDOI

Debrisoquine oxidation phenotype during neuroleptic monotherapy

TL;DR: The results confirm the fact that phenothiazines, and to a lesser extent haloperidol, inhibit the oxidative metabolism of debrisoquine and show also that clothiapine administration does not disturb the debrisquine metabolic ratio.
Journal ArticleDOI

Association between the oxidative polymorphism and early onset of Parkinson's disease

TL;DR: The combined effect of environmental toxins and CYP2D6 in the cause of Parkinson's disease is suggested, indicating that the oxidative polymorphism is related to early‐onset but not to late-onset Parkinson's Disease.
Journal ArticleDOI

Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers

TL;DR: The genetic polymorphism of NAT2 is a relevant factor in the risk for developing HCC (inverse odds ratio slow vs rapid = 1.8; 95% CI 1.1-3.0) and the additional determination of alleles of the cytochrome P450 2D6 (CYP2D6) gene in the same subjects confirmed the previous findings that subjects with two active CYP2D 6 genes are at increased risk of developing H CC.
Journal ArticleDOI

Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

TL;DR: The presence of CYP1A2, CYP2C9, CyP2D6 and CYP3A in brain, as well as the possible existence of local brain metabolism, are reviewed and the putative implications of endogenous modulation of these isoenzymes by neurotransmitters are discussed.
Journal ArticleDOI

Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.

TL;DR: The presence of carcinogen-metabolizing enzymes in human prostate with a high interindividual variability may be involved in the regulation of local levels of carcinogens and mutagens and may underlie interindividual differences in cancer susceptibility.